Live Breaking News & Updates on Low Intensity Chemotherapy

Stay updated with breaking news from Low intensity chemotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment. ....

Bijal Shah , Hagop Kantarjian , Expert Insights , Newly Diagnosed , Frontline Therapy , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Tki Therapy , Comparative Trials , Hypercvad Therapy , Broad Acting Tki , Compound Mutations , Phallcon Study , Phallcon Trial , Low Intensity Chemotherapy , Imatinib Therapy , Ponatinib Therapy , Dasatinib Therapy , Novel Therapy , Combination Therapy ,